Revenue
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Carl Zeiss Meditec AG (AFX)
Price€31.56Cached quote
Net income
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | €2.23B | €2.07B | €2.09B | €1.90B | €1.65B | €1.34B | €1.46B | €1.28B | €1.19B | €1.09B | €1.04B | €909.3M | €906.4M | €861.9M | €758.8M | €676.7M |
| Gross profit | €1.18B | €1.09B | €1.21B | €1.13B | €967.2M | €745.5M | €831.9M | €710.4M | €656.7M | €579.5M | €539.7M | €488.4M | €487.8M | €461.4M | €414.8M | €358.7M |
| Gross margin | 52.76% | 52.69% | 57.71% | 59.26% | 58.73% | 55.83% | 57.00% | 55.46% | 55.19% | 53.25% | 51.89% | 53.71% | 53.82% | 53.53% | 54.67% | 53.01% |
| Research & development | €326.3M | €343.1M | €349.3M | €291.4M | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating expenses | €951.9M | €894.2M | €857.6M | €730.7M | €593.6M | €568.0M | €567.2M | €513.3M | €475.9M | €425.2M | €409.1M | €367.7M | €353.9M | €338.5M | €311.3M | €272.1M |
| Operating income | €223.3M | €194.4M | €348.1M | €396.9M | €373.6M | €177.6M | €264.7M | €197.1M | €180.8M | €154.3M | €130.6M | €120.7M | €133.9M | €122.9M | €103.6M | €86.6M |
| Operating margin | 10.02% | 9.41% | 16.66% | 20.86% | 22.69% | 13.30% | 18.14% | 15.39% | 15.20% | 14.18% | 12.56% | 13.27% | 14.77% | 14.26% | 13.65% | 12.80% |
| EBITDA | €346.9M | €403.1M | €501.9M | €482.9M | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA margin | 15.57% | 19.51% | 24.02% | 25.38% | — | — | — | — | — | — | — | — | — | — | — | — |
| Net income | €142.3M | €180.2M | €292.0M | €295.9M | €237.5M | €123.4M | €160.6M | €126.2M | €135.8M | €100.0M | €65.6M | €79.2M | €99.1M | €76.4M | €72.3M | €59.6M |
| Net profit margin | 6.39% | 8.72% | 13.98% | 15.55% | 14.42% | 9.24% | 11.00% | 9.86% | 11.41% | 9.19% | 6.30% | 8.71% | 10.94% | 8.86% | 9.52% | 8.81% |
| Basic EPSper basic share | €1.58 | €2.00 | €3.25 | €3.29 | €2.64 | €1.37 | €1.79 | €1.41 | €1.50 | €1.21 | €0.77 | €0.92 | €1.15 | €0.88 | €0.82 | €0.68 |
| Diluted EPSper diluted share | €1.61 | €2.00 | €3.25 | €3.29 | €2.64 | €1.37 | €1.79 | €1.41 | €1.57 | €1.21 | €0.77 | €0.92 | €1.15 | €0.88 | €0.82 | €0.68 |
Owners
Reported major voting-rights holders
2.92%of voting rights
SMALLCAP World Fund, Inc.Notified Jan 21, 2026
View holders
| Holder | Voting rights |
|---|---|
SMALLCAP World Fund, Inc. | 2.92%Jan 21, 2026 · 2.61M votes |
The Capital Group Companies, Inc. | 2.61%Jan 22, 2026 · 2.33M votes |
The Goldman Sachs Group, Inc. | 0.68%Sep 30, 2026 · 608.72K votes |
These are threshold-crossing notices, not a complete ownership register. Percentages show issuer voting rights held through the listed share class, exclude financial instruments, and come from different dates. Positions may overlap.
Gray completes the 100% scale; it is not an estimate of other owners.
Source: Issuer voting-rights announcements via EQS ↗Updated Oct 21, 2026